Marketresearchnews

Thursday, 15 November 2018

Microbiology Testing Market 2018 Market Challenge, Driver, Trends & Forecast to 2023

Market Scenario

The rising costs of surgeries and overall healthcare has induced the need for hospitals to lean towards technology to reduce the burden. Microbiology Testing (RCM) is a system in the healthcare cycle which relies on electronic health records (EHRs) and automation to expedite outpatient billing and reduce wait times. The global Microbiology Testing market is touted to exhibit a healthy 12.2% CAGR during the assessment period (2017-2027), as per a new market report by Market Research Future (MRFR).

The growing numbers of hospitals and clinics, rising adoption rate of RCM software, recovery audits, and preference for integrated healthcare systems are factors expected to drive market demand during the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/697

Key Players for Global Microbiology testing Market:

Alere (US)

BD (US)

Beckman Coulter, Inc. (US)

Cepheid (US)

Thermo Fisher Scientific Inc. (US)

F. Hoffmann-La Roche Ltd (Switzerland)

Biomérieux SA (France)

Segments:

Global Microbiology testing Market has been segmented on the basis of type which comprise Instruments, Chemicals & Reagents, Consumables & Accessories, and others. On the basis of application, it is segmented into, Gastrointestinal Infections, Respiratory Infections, Urinary tract Infections, Sexually Transmitted Infections, Others. On the basis of end user, it is segmented into, Hospital based laboratory, Independent laboratory, and Academics & Research Institutes.

Regional Analysis of Global Microbiology testing Market:

Considering the global scenario of the market, North America was holding largest market share of 37.9% in global Microbiology testing market in 2016. Asia-Pacific is second largest and fastest growing market in global Microbiology testing market. APAC is expected to grow at a CAGR of 12.1% during 2017-2023. Europe was second largest microbiology testing market and is expected to grow at a significantly during the forecast period. On the other hand. Middle East and Africa (ME&A) microbiology testing market was growing lower than global average and expected to grow at steady pace.

Browse Complete 129 Pages Premium Research Report Enabled with 129 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697

Detailed Table of Contents:

TABLE OF CONTENTS

1 Report Prologue

2 Introduction

2.1 Scope Of Study 17

2.2 Research Objective 17

2.3 Assumptions & Limitations 17

2.3.1 Assumptions 17

2.3.2 Limitations 17

2.4 Market Structure 18

3 Research Methodology

3.1 Primary Research 21

3.2 Secondary Research 21

3.3 Market Size Estimation 21

3.3.1 Market Share Analysis 22

3.4 Market Pricing Approach 23

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Technological Advancements

4.2.2 Rising Cases Of Infectious Diseases

4.2.3 Surveillance Programs For Disease Control

4.2.4 Rising Stringency Of Standards

4.2.5 Weakness Of Traditional Laboratory Techniques

...Continued

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Lung Cancer Market 2018 Share, Trend, Segmentation and Forecast to 2023

Market Synopsis of Global Lung Cancer Market:

Market Scenario:

The Lung cancer Market is growing mainly due to the changing lifestyle, and environmental pollution. According to a recent study report published by the Market Research Future, The lung cancer market is booming and expected to gain prominence over the forecast period. The market is forecasted to demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR of 13.5% during the anticipated period (2017 – 2023).

Get Reports Sample Copy @ https://www.marketresearchfuture.com/sample_request/1185

Lung cancer is a malignant lung tumor characterized by uncontrolled cell growth in lung tissue with symptoms such as coughing, weight loss, and fatigue and chest pain. The two types of lung cancers are small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). The NSCLC type accounts for almost 80% of the total lung cancers. The cure rates for the two types of lung cancers exchange their positions with the SCLC being the most malignant. The cure rates also depend on the stage of cancer detection with rates varying by 55% for first stage to just 1% for stage four.

Almost 85% of cases of lung cancer are due to long-term tobacco smoking. Cigarette smoke contains at least 73 known carcinogens. Other factors causing lung cancer are genetic factors and exposure to triggers and carcinogens such as radon gas, asbestos, radioactive materials, second-hand smoke, or air pollution. It has also been demonstrated that passive smokers have a 20–30% increase in risk.

The treatments for lung cancer include surgery, chemotherapy, and radiotherapy with NSCLC responding better to surgery and SCLC usually responding better to chemotherapy and radiotherapy. Notably, smoking is the primary driver for the rising cases of lung cancer. According to World Health Organization (WHO) tobacco kills more than 7 million people each year of which more than 6 million deaths are the result of direct tobacco use. Lung cancer is the leader with a whopping 37% of deaths. Of more concern is the rising rates of lung cancer due to passive smoking.

Other push factors such as, environmental pollution, rising cases of infections, growing rates of early detection and awareness, rising rates of fast growing lung cancer, and reimbursements and growing health insurance are also fuelling the growth of the market.

Despite these drivers, poor efficacy, cure rates and side effects of present treatment, high failure rates of lung transplant surgeries, high malignant nature and faster growth of lung cancer, poor life expectancy and quality of life of patients undergoing lung cancer treatment, and scarcity of lung organ and long waiting lines are expected to decline the market growth. According to American Society of Clinical Oncology (ASCO) the 5-year survival rate for stage I NSCLC is about 47% which falls drastically to 10% for stage III. The 5-year survival rate for stage IV NSCLC is just around 1%.

Key Players for Global Lung Cancer Market:

· F. Hoffmann-La Roche AG

· Novartis

· PFIZER INC

· Merck & Co., Inc.

· BRISTOL-MYERS SQUIBB

· ELI Lilly and Company

· Sanofi

Segments:

Global Lung Cancer Market has been segmented on the basis of types which comprises of SCLC and NSCLC. On the basis of treatments it is segmented into Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT) and Laser therapy. On the basis of end users, it includes Hospitals & Clinics, Cancer Research Centers and Laboratories.

Regional Analysis:

The global market for Lung Cancer is growing steadily. The global lung cancer market on the basis of region comprises of North America, Europe, Asia Pacific and Middle East & Africa. The global market for Lung Cancer is growing with the CAGR of 13.5% during the forecast period from 2017-2023. NSCLC is the most common type of lung cancer globally. The global Lung Cancer market reached USD 36929.8 million in 2023 from 15219.7 million in 2016. Europe region captured the second largest market globally and is expected to reach USD 8,536.3 million by 2023 due to the growing demand and need for lung cancer drugs, and the growing prevalence of lung cancer.

Browse Complete 108 Pages Premium Research Report Enabled with 121 Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/lung-cancer-market-1185

Detailed Table Of Contents

1 Report Prologue

2 Introduction

2.1 Research Objective

2.2 Assumptions & Limitations

2.2.1 Assumptions

2.2.2 Limitations

2.3 Market Structure

3 Research Methodology

3.1 Primary Research

3.2 Secondary Research

4 Porters Five Forces

4.1 Introduction

4.2 Bargaining Power Of Buyer

4.3 Bargaining Power Of Suppliers

4.3.1 Threat From Substitute

4.3.2 Threat From A New Entrant

4.3.3 Intensity Of Competitive Rivalry

5 Market Dynamics

5.1 Drivers

5.1.1 Smoking

5.1.2 Environmental Pollution

5.1.3 Rising Cases Of Infections

5.1.4 Growing Rates Of Early Detection And Awareness

5.1.5 Rising Rates Of Fast Growing Lung Cancer

5.1.6 Reimbursements And Growing Health Insurance

...Continued

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Intravenous (IV) Solution Market, Trends, Absolute Opportunity and Value Chain 2018

Market Scenario:

Intravenous (IV) Solution are intended to be administered to the patients which are deficient in nutrients or at the time of serious dehydration. These solutions are given to the patients whose fluid volume or body nutrients falls. Many companies manufactures packaged intravenous fluids or products or compounds which can be mixed with sterile water to prepare a solution for intravenous administration. The market for intravenous solutions is growing swiftly.

The market for Intravenous (IV) Solution is expected to reach USD 11,511.2 million by 2022 and is expected to grow at a CAGR of 7.69% during the forecast period 2016-2022. The factors which drive the growth of the market are the rising prevalence of chronic diseases, rising acceptance of vitamin C intravenous treatment therapy to treat colorectal cancer.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1235

Key Players for Global Intravenous (IV) Solution Market:Some of the key players in this market are: ICU Medical, Inc. (U.S.), B. Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), Baxter (U.S.), Amanta Healthcare (India), Terumo Medical Corporation (Tokyo), Grifols S.A. (Spain) and others.

Segments:Global Intravenous (IV) Solution Market has been segmented on the basis of type which comprises of total parenteral solution, peripheral parenteral solution. On the basis of nutritional content the market is segmented into amino acid solution, carbohydrates, vitamins & minerals, parenteral lipid emulsion and others. On the basis of end user the market is segmented into hospitals & clinics, ambulatory and home care.

Regional Analysis of Global Intravenous (IV) Solution Market:The global market for Intravenous (IV) Solution is growing rapidly. The market for Intravenous (IV) Solution is growing with the CAGR of 7.69% during the forecast period from 2016-2022. North America accounts for largest market share in 2015 and is expected to reach USD 4,276.5 million in 2016. This growth is attributed to the factors such as high IV consumption number, high prevalence of chronic diseases.
Asia-Pacific region is the fastest growing market for Intravenous (IV) Solution Market, which is expected to grow at a CAGR of 8.34% during the forecast period from 2016 to 2022 is due to the emergence of high-quality and better healthcare infrastructure and institutions in this region.

Browse Complete 121 Pages Premium Research Report Enabled with 138 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/intravenous-solution-market-1235

Detailed Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

Chapter 4. Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing Prevalence Of The Chronic Diseases

4.2.2 Rise Of Cholera

4.2.3 Growing Acceptance Of Vitamin C Intravenous For Colorectal Cancer

4.3 Restraints

4.3.1 Presence Of Stringent Government Regulations

4.4 Opportunities

4.4.1 Rising Continuous Demand Of Iv Solutions In U.S.

4.5 Challenge

4.5.1 Increasing Vitamin C Intravenous Therapy Prices

4.6 Mega Trends

4.7 Macroeconomic Indicators

...Continued

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hematocrit Test Market 2018 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario:

Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5553

The global hematocrit test market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Regional Analysis of the Global Hematocrit Test Market

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services. In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse Complete 110 Pages Premium Research Report Enabled with 77 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

Detailed Table of Contents:

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

...Continued

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Hallux Rigidus Market Trends, Size and Growth Analysis 2018 To 2023

Hallux rigidus is an arthritic condition often leading to pain and stiffness within the joint located behind the big toe. Hallux rigidus is a syndrome related to degeneration of the first MTP joint. It leads to a limitation in joint range of motion and painful ambulation.

Hallux rigidus can be caused by either a traumatic injury or through overuse of the foot. Overpronation or too much stress on the joint is one of the reasons. Repetitive weight bearing in a dorsiflexed position such as when walking up mountains or driving forward in a rugby scrum or similar conditions can be a factor.

Other causes include traumatic injury such as stubbing the big toe causing cartilage damage in the joint. Rheumatoid arthritis which is inflammatory wear and tear of the joint, as well as gout which is a form of arthritis caused by excessive uric acid in the joint, can also cause hallux rigidus.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5552

The global hallux rigidus market is majorly driven by increasing geriatric population, rising diabetic mass, and rising road mishaps. According to the U.S. Population Reference Bureau, the number of Americans aged 65 and older is projected to 98 million by 2060 from 46 million as of 2014. Similarly, the 65-and-older age group will rise to nearly 24 percent by 2030 from 15 percent as of 2015.

The global hallux rigidus market is expected to grow at a CAGR of 7.6% during the forecast period.

Segments

The global hallux rigidus infection market is segmented on the basis of treatment, diagnosis, and end-users.

On the basis of the treatment, the market is segmented into non-surgical treatment and surgical treatment. Further, the non-surgical treatment is sub-segmented into shoe modifications, orthotic devices, medications, injection therapy, and physical therapy. And the surgical treatment is sub-segmented into bone spur removal (cheilectomy), joint fusion (arthrodesis), joint resurfacing (interpositional arthroplasty), and joint replacement (arthroplasty).

On the basis of diagnosis, the market is segmented into X-ray, CT scan, and MRI.

On the basis of the end users, the market is segmented into hospitals & surgical centers, home cares, and orthopedic specialty clinics.

Regional Analysis

North America holds the maximum share of hallux rigidus market in the Americas region. On a regional basis, Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of geriatric population and growing diabetic mass has increased the scope of the hallux rigidus market in North America.

Europe holds the second largest share in the global hallux rigidus market. The European market is expected to observe a healthy growth during the forecasted period. Factors such as availability of advanced treatment facilities, and skilled medical professionals is propelling the growth of hallux rigidus market in Europe. Additionally, increasing government funding and extensive research and development in terms of healthcare is likely to boost the market growth.

Asia Pacific is expected to be the fastest growing market owing to increasing prevalence of chronic diseases such as diabetes is the major driver for the market growth. India is the fastest growing region owing to an increasing population. Rising awareness about the health and availability of new treatment methods is likely to drive the market in this region.

The Middle East & Africa is expected to show a slow growth in the market . Major factors that are hampering the growth are lack of awareness, and limited access and availability of treatment facilities. In the Middle East, United Arab Emirates has garnered the largest market share owing to the development of healthcare industry and rising number of specialty care centers.

Key Players

Some of the key players in fu market are are DePuy Synthes Companies, Stryker, Zimmer Biomet, Smith & Nephew, Wright Medical Group N.V., Advanced Orthopaedic Solutions, Integra LifeSciences Corporation, and Acumed, Bioretec Ltd. among others.

Browse Complete 200 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/hallux-rigidus-market-5552

Detailed Table of Contents:

Report Prologue
Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

...Continued!

About US:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com